Tofacitinib's infectious profile: concerns for clinical practice

The Lancet Rheumatology

Volumn 2, Issue 2, 2020, Pages e65-e67

  Favalli, Ennio Giulio ^a  

^a Gaetano Pini CTO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; JANUS KINASE INHIBITOR; RECOMBINANT VACCINE; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR;

AGED; AUTOIMMUNE DISEASE; CLINICAL PRACTICE; COHORT ANALYSIS; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RISK; MORBIDITY; MORTALITY; NOTE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT;

EID: 85078283097     PISSN: None     EISSN: 26659913     Source Type: Journal    
DOI: 10.1016/S2665-9913(20)30001-1     Document Type: Note

References (10)

1. Singh, JA, Cameron, C, Noorbaloochi, S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 386 (2015), 258–265.
2. European Medicines Agency. EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots. 2019. https://www.ema.europa.eu/en/news/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots (accessed Dec 20, 2019).
3. Pawar, A, Desai, RJ, Gautam, N, Kim, SC, Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study. Lancet Rheumatol, 2020 published online Jan 13. https://doi.org/10.1016/S2665-9913(19)30137-7.
4. Bechman, K, Subesinghe, S, Norton, S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology 58 (2019), 1755–1766.
5. Strand, V, Ahadieh, S, French, J, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther, 17, 2015, 362.
6. Weinberg, A, Levin, MJ, VZV T cell-mediated immunity. Curr Top Microbiol Immunol 342 (2010), 341–357.
7. Winthrop, KL, Yamanaka, H, Valdez, H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 66 (2014), 2675–2684.
8. Curtis, JR, Xie, F, Yang, S, et al. Risk for Herpes zoster in tofacitinib-treated rheumatoid arthritis patients with and without concomitant methotrexate and glucocorticoids. Arthritis Care Res 71 (2019), 1249–1254.
9. Furer, V, Rondaan, C, Heijstek, MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 79 (2019), 39–52.
10. Lacaille, D, Guh, DP, Abrahamowicz, M, Anis, AH, Esdaile, JM, Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 59 (2008), 1074–1081.